Summary： LncRNAH19 has been implicated as having both oncogenic and tumor suppression properties in cancer. LncRNAH19 transcripts also serve as a precursor for miR-675. However, it is unknown whether LncRNAH19 and mi...Summary： LncRNAH19 has been implicated as having both oncogenic and tumor suppression properties in cancer. LncRNAH19 transcripts also serve as a precursor for miR-675. However, it is unknown whether LncRNAH19 and miR-675 are involved in the migration and invasion of hepatocellular carcinoma （HCC） cells. The purpose of this study was to investigate the effect and mechanism of LncRNAH19 and miR-675 on migration and invasion of HCC cells. The migration and invasion of HCC cells were measured by Transwell migration and invasion assays after transfection of HCC cells with miR-675 inhibitors and LncRNAH19siRNA. The levels of LncRNAH19 and miR-675 were detected by quantitative reverse transcriptase real-time polymerase chain reaction （qRT-PCR）, and the protein expression of AKT, GSK-3[3 and Cdc25A by Western blotting analysis. The expression levels of LncRNAHI9 and miR-675 were higher in MHCC-97H cells than in L02, Huh-7 and HepG2 cells. Transwell migration assay revealed that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the migration of HCC cells （P〈0.01） as compared with the control group. Transwell invasion assay demonstrated that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the invasion of HCC cells （P〈0.01） as compared with the control group. Western blotting analy- sis showed that the expression levels of AKT and Cdc25A were significantly increased （P〈0.05）, and the expression level of GSK-313 was significantly decreased （P〈0.05） after treatment with miR-675 inhibitors and LncRNAH19siRNA as compared with the control group. These findings suggested that inhibition of LncRNAH 19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3[3/Cdc25A signaling pathway.展开更多
基金supported by grants from the National Natural Science Foundation of China(Nos.81071871,81101862 and 81172079)Natural Science Foundation of Guangdong Province,China(Nos.S2013010016831,and 10451008901006014)+4 种基金Science and Technology Planning Project of Guangdong Province,China(No.2009B030801014,2010B060500007 and 2011B060300012)the Foundation of the Health Department of Guangxi Province,China(No.Z2007212)the Foundation of Scientific Research and Technology Development Project of Guilin,China(key scientific and technological projects and trial production of new products,No.20110321)the Foundation of Scientific Research and Technology Development Project of Guangxi Province,China(No.GuiKeGong1355005-3-5)Foundation for Youth Teacher by Sun Yat-Sen University(No.11ykpy16)
文摘Summary： LncRNAH19 has been implicated as having both oncogenic and tumor suppression properties in cancer. LncRNAH19 transcripts also serve as a precursor for miR-675. However, it is unknown whether LncRNAH19 and miR-675 are involved in the migration and invasion of hepatocellular carcinoma （HCC） cells. The purpose of this study was to investigate the effect and mechanism of LncRNAH19 and miR-675 on migration and invasion of HCC cells. The migration and invasion of HCC cells were measured by Transwell migration and invasion assays after transfection of HCC cells with miR-675 inhibitors and LncRNAH19siRNA. The levels of LncRNAH19 and miR-675 were detected by quantitative reverse transcriptase real-time polymerase chain reaction （qRT-PCR）, and the protein expression of AKT, GSK-3[3 and Cdc25A by Western blotting analysis. The expression levels of LncRNAHI9 and miR-675 were higher in MHCC-97H cells than in L02, Huh-7 and HepG2 cells. Transwell migration assay revealed that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the migration of HCC cells （P〈0.01） as compared with the control group. Transwell invasion assay demonstrated that the miR-675 inhibitor and LncRNAH19siRNA could significantly increase the invasion of HCC cells （P〈0.01） as compared with the control group. Western blotting analy- sis showed that the expression levels of AKT and Cdc25A were significantly increased （P〈0.05）, and the expression level of GSK-313 was significantly decreased （P〈0.05） after treatment with miR-675 inhibitors and LncRNAH19siRNA as compared with the control group. These findings suggested that inhibition of LncRNAH 19 and miR-675 expression can promote migration and invasion of HCC cells via AKT/GSK-3[3/Cdc25A signaling pathway.
